Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Intellia Therapeutics stock | 34.35

Own Intellia Therapeutics stock in just a few minutes.

Posted

Fact checked

Intellia Therapeutics, Inc is a biotechnology business based in the US. Intellia Therapeutics shares (NTLA) are listed on the NASDAQ and all prices are listed in US Dollars. Intellia Therapeutics employs 270 staff and has a trailing 12-month revenue of around USD$62.3 million.

How to buy shares in Intellia Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Intellia Therapeutics. Find the stock by name or ticker symbol: NTLA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intellia Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$34.35, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intellia Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Intellia Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Intellia Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Intellia Therapeutics's share price has had significant positive movement.

Its last market close was USD$34.35, which is 61.02% up on its pre-crash value of USD$13.39 and 274.18% up on the lowest point reached during the March crash when the shares fell as low as USD$9.18.

If you had bought USD$1,000 worth of Intellia Therapeutics shares at the start of February 2020, those shares would have been worth USD$977.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,799.53.

Intellia Therapeutics share price

Use our graph to track the performance of NTLA stocks over time.

Intellia Therapeutics shares at a glance

Information last updated 2020-11-26.
Latest market close USD$34.35
52-week range USD$9.18 - USD$36.64
50-day moving average USD$27.7842
200-day moving average USD$22.3299
Wall St. target price USD$35.96
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.004

Buy Intellia Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intellia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intellia Therapeutics price performance over time

Historical closes compared with the close of $34.35 from 2020-11-16

1 week (2020-11-20) 6.22%
1 month (2020-10-30) 43.48%
3 months (2020-08-28) 60.97%
6 months (2020-05-28) 96.06%
1 year (2019-11-27) 102.00%
2 years (2018-11-28) 100.99%
3 years (2017-11-28) 59.77%
5 years (2015-11-27) N/A

Intellia Therapeutics financials

Revenue TTM USD$62.3 million
Gross profit TTM USD$-65,310,000
Return on assets TTM -19.24%
Return on equity TTM -39.76%
Profit margin -193.01%
Book value $5.607
Market capitalisation USD$2.1 billion

TTM: trailing 12 months

Shorting Intellia Therapeutics shares

There are currently 12.9 million Intellia Therapeutics shares held short by investors – that's known as Intellia Therapeutics's "short interest". This figure is 0.8% up from 12.8 million last month.

There are a few different ways that this level of interest in shorting Intellia Therapeutics shares can be evaluated.

Intellia Therapeutics's "short interest ratio" (SIR)

Intellia Therapeutics's "short interest ratio" (SIR) is the quantity of Intellia Therapeutics shares currently shorted divided by the average quantity of Intellia Therapeutics shares traded daily (recently around 985341.43730887). Intellia Therapeutics's SIR currently stands at 13.08. In other words for every 100,000 Intellia Therapeutics shares traded daily on the market, roughly 13080 shares are currently held short.

However Intellia Therapeutics's short interest can also be evaluated against the total number of Intellia Therapeutics shares, or, against the total number of tradable Intellia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intellia Therapeutics's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Intellia Therapeutics shares in existence, roughly 210 shares are currently held short) or 0.2975% of the tradable shares (for every 100,000 tradable Intellia Therapeutics shares, roughly 298 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Intellia Therapeutics.

Find out more about how you can short Intellia Therapeutics stock.

Intellia Therapeutics share dividends

We're not expecting Intellia Therapeutics to pay a dividend over the next 12 months.

Intellia Therapeutics share price volatility

Over the last 12 months, Intellia Therapeutics's shares have ranged in value from as little as $9.18 up to $36.64. A popular way to gauge a stock's volatility is its "beta".

NTLA.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intellia Therapeutics's is 1.5834. This would suggest that Intellia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intellia Therapeutics overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site